Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01554696 · ClinicalTrials.gov registry record · Phase 2
A Study to Evaluate the Safety and Efficacy of ASP015K in Moderate to Severe Rheumatoid Arthritis Subjects Who Have Had an Inadequate Response to Methotrexate
A Phase 2 study, sponsored by Astellas Pharma.
- Completed
- Registry status
- Phase 2
- Development phase
- 379
- Enrollment target
NCT01554696 is a Phase 2 study that has completed, run by Astellas Pharma. The registered enrollment target is 379 participants.
The verdict
NCT01554696, a Phase 2 study, has completed, sponsored by Astellas Pharma.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 379 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the safety and efficacy of ASP015K in moderate to severe rheumatoid arthritis subjects who are methotrexate-inadequate responders (MTX-IR).
Interventions
- DRUG Placebo
- DRUG methotrexate
- DRUG peficitinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 379 participants |
| Start Date | 2012-07-06 |
| Est. Completion | 2014-02-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01554696
The ClinicalTrials.gov registry entry for NCT01554696 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 379 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Astellas Pharma, which has 165 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT01554696 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01554696 about?
NCT01554696 is a clinical study titled "A Study to Evaluate the Safety and Efficacy of ASP015K in Moderate to Severe Rheumatoid Arthritis Subjects Who Have Had an Inadequate Response to Methotrexate". The purpose of this study is to evaluate the safety and efficacy of ASP015K in moderate to severe rheumatoid arthritis subjects who are methotrexate-inadequate responders (MTX-IR).
What is the current status of trial NCT01554696?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 379 participants. The study started on 2012-07-06. Estimated completion is 2014-02-11.
What interventions are being tested in trial NCT01554696?
The interventions under investigation include: Placebo (DRUG), methotrexate (DRUG), peficitinib (DRUG).
Who is sponsoring clinical trial NCT01554696?
This trial is sponsored by Astellas Pharma, which has 165 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.